ECCO 2025

Eating is part of life – and of special therapeutic importance in IBD patients!

The importance of endoscopic surveillance – current techniques and a bright future?

Personalized dosing of infliximab in moderate to severe UC

Surgical approaches in IBD – all questions solved?

No treatment choices anymore? Efficacy and safety of autologous hematopoietic stem cell transplantation in CD

Anti-TL1a – a new treatment option in IBD and unsolved questions

New UC-kids on the block: a IL7 receptor antagonist & an anti-TNF/anti-IL-23 bispecific AB

Comparative efficacy between biologics in UC – the need for H2H-trials

The perfect dosing of our drugs – data on ustekinumab and vedolizumab in CD

Update on fistulizing disease

Urgency – what is hen and what is egg?

Old vs. new – ustekinumab vs. modern IL23

What is the best treatment goal for moderate to severe UC?

Combination therapies – on the way to the holy grail?

Comparative efficacy and safety – do we need to reassess JAKis?

Kono-S anastomosis is not superior to side-to-side anastomosis to prevent endoscopic recurrence in CD

Subcutaneous therapy with guselkumab for Crohn's disease and ulcerative colitis

Autologous HSCT – still an option for refractory CD?

Subcutaneous induction with guselkumab in CD is effective!

The need for early treatment in Crohn’s disease – a Chinese perspective

Dose escalation of vedolizumab in CD is not effective

Early CD treatment with vedolizumab

HSCT autologue – toujours une option pour la maladie de Crohn réfractaire?

La anastomosis Kono-S no es superior a la anastomosis side-to-side para prevenir la recurrencia endoscópica en la enfermedad de Crohn

Rola wczesnej terapii choroby Leśniowskiego-Crohna – dane chińskie

Subkutane Therapie mit Guselkumab bei Morbus Crohn und Colitis ulcerosa

Obefazimod maintenance treatment: a new approach

Appendectomy – a good option for UC

Long-term efficacy and safety of a lower obefazimod maintenance dose

Personalized dosing in acute UC

How to treat UC patients after failure of a s.c. anti-TNF?

First combination of upadacitinib and vedolizumab in ulcerative colitis

Subcutaneous therapy with guselkumab for Crohn's disease and ulcerative colitis

Obefazimod in der Erhaltung: Neuer Ansatz

Long-term efficacy and safety of a lower obefazimod maintenance dose

Erste Kombination von Upadacitinib und Vedolizumab bei Colitis ulcerosa

Subkutane Therapie mit Guselkumab bei Morbus Crohn und Colitis ulcerosa

Appendektomie – eine gute Option bei Colitis Ulcerosa

Comment traiter la RCH après l'échec d'un anti-TNF s.c.?

New mode of action for treating UC

Lusvertikimab – a first-in-class IL7 receptor antagonist for patients with UC

New treatments – fast forward to the future

SOR102 – a novel oral bispecific antibody in patients with active UC

A new class of drugs: anti-TL1A antibodies

s.c.? i.v.? Just swallow it! News from the oral bispecific anti-TNFα and anti-IL-23p19 antibody SOR102

טיפולים חדשים- fast forward לעתיד

s.c.? i.v.? Einfach schlucken! Neues vom oralen bispezifischen anti-TNFα und anti-IL-23p19 Antikörper SOR102

SOR102 – un nuovo anticorpo bispecifico orale in pazienti con UC attiva

Eine neue Substanzklassen: Anti-TL1A Antikörper

Lusvertikimab – un antagonista del recettore IL7 di prima classe per i pazienti con UC

Nouveau mode d'action pour le traitement de la RCH

What is the best treatment goal for moderate to severe UC?

Association between histologic response and histo-endoscopic / clinical outcomes after Mirikizumab induction in CD

Defining radiological healing in perianal fistulising Crohn’s Disease: a global modified Delphi consensus

Mirikizumab demonstrates rapid improvements in bowel urgency in moderately-to-severely active UC

Comprehensive approach necessary to treat our patients the best way possible!

Minimal Residual Disease: a new treatment goal in IBD?

Minimal Residual Disease: ein neuer Endpunkt bei CED?

Mirikizumab demonstrates rapid improvements in bowel urgency in moderately-to-severely active UC

Was ist der beste Therapieendpunkt bei moderater bis schwerer UC?

Definiendo la curación radiológica en enfermedad de Crohn perianal fistulizante: resultados de un consenso Delphi modificado global

גישה כוללנית הכרחית לטיפול בחולים בדרך המיטבית

Tasty&Healthy – the next step towards anti-inflammatory diets!

Tasty&Healthy diet is better tolerated than exclusive enteral nutrition

Fibre consumption and the risk of developing CD

A low emulsifier diet is a treatment for moderate to severe CD

Tasty&Healthy – der nächste Schritt zu einer entzündungshemmenden Ernährung!

Spożycie błonnika a ryzyko zachorowania na chorobę Leśniowskiego-Crohna

PODIUM: effectiveness & safety of 2nd line vedolizumab or ustekinumab or JAKies after anti-TNF therapy

Comparative efficacy of infliximab and vedolizumab after failure of a first anti-TNF in UC patients

Effectiveness & safety of advanced combination therapy in pts. with refractory IBD or concomittant IMID

ASTRO study established the efficacy of guselkumab subcutaneous induction (week 12) in UC patients

Etrasimod improves clinical, endoscopic and histologic outcomes in UC

PODIUM: efficacia e sicurezza di Vedolizumab o Ustekinumak o JAKi di seconda linea dopo terapia anti-TNF

Efficacia e sicurezza di una terapia combinata avanzata nelle mallatie inflammatorie croniche intestinali refrattarie

El estudio ASTRO demuestra la eficacia de Guselkumab en inducción por vía subcutánea (semana 12) en pacientes con colitis ulcerosa

Eficacia comparativa de infliximab vs. vedolizumab tras fallo a un primer anti-TNF en pacientes con colitis ulcerosa

Effectiveness & safety of advanced combination therapy in pts. with refractory IBD or concomittant IMID

Infliximab induction fails to reach target drug level in perinal fistulizing CD

Dose escalation of primary non-responders is not effective!

Second line treatment for perianal Crohn's disease

Optimizing biologics in CD – is it relevant for all?

Mancato aumento dei livelli terapeutici di IFX nella malattia di Crohn complicata da malattia perianale

Efficacia e sicurezza di una terapia combinata avanzata nelle mallatie inflammatorie croniche intestinali refrattarie

Zweitlinie bei Crohn-Fisteln

אופטימיזציה של תכשירים ביולוגים במחלת קרוהן-האם מתאים לכולם?

Psychological factors and the risk of IBD flare

Risk of IMID associated with anti-TNF and ustekinumab in CD

Rischio di IMID associato al trattamento con anti-TNF e con ustekinumab

Czynniki psychologicne a ryzyko zaostrzenia IBD

αvβ6 – new biomarker in prediciting, staging and monitoring CD

How to detect preneoplastic lesions by coloscopy

Comment détecter les lésions prénéoplasiques par coloscopie

αvβ6 – ein neuer Biomarker zur Prädiktion, Staging und Monitoring von Morbus Crohn

A new classification of IBD – 20 years later!

Une nouvelle classification des MICI – 20 ans après!

HLA typing – tailoring treatment a step forward?

Identification of CD and UC specific clonotypes

סיווג HLA-התקדמות בטיפול מותאם אישית?

Identificazione di clonotipi specifici nella malattia di Crohn e nella colite ulcerosa